Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | SHBG | P04278 | 2/20 | 0.42 |
| ▸ | ESRRA | P11474 | 3/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ESRRB | O95718 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682190 | 1.00 | ESR1 (0.47) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL5677657 | 1.00 | ESR1 (0.47) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL5679418 | 1.00 | ESR1 (0.47) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL5682202 | 0.92 | ESR1 (0.50) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL5681884 | 0.92 | ESR1 (0.50) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL5872764 | 0.92 | ESR1 (0.50) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL5682197 | 0.92 | ESR1 (0.50) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL6260970 | 0.88 | ESR1 (0.46) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL6258409 | 0.88 | ESR1 (0.46) | ESR1ESR2HDAC3HDAC6SHBG | |
| SCHEMBL5679603 | 0.88 | ESR1 (0.44) | ESR1ESR2HDAC3HDAC6SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | US | claimed |
| US-7109360-B1 | 16-hydroxyestratrienes as selectively active estrogens | SCHERING AG (DE) | 2006-09-19 | — | — | US | claimed |
| EP-1144431-B1 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | SCHERING AG (DE) | 2005-12-21 | — | — | EP | claimed |
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | US | disclosed |
| US-7109360-B1 | 16-hydroxyestratrienes as selectively active estrogens | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| EP-1144431-B1 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | SCHERING AG (DE) | 2005-12-21 | — | — | EP | disclosed |
| EP-1580192-A2 | 16-Hydroxyestratrienes as selective estrogens | Schering AG (DE) | 2005-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | ESR1, ESR2, ESRRA | ESR1 1/4885ESR2 2/4885HDAC3 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.